Pandemic Cessation Act

Bill: 117-hr-6009
Sponsor: full_name: Rep. Schweikert, David [R-AZ-6]
Introduced: 2021-11-17
Policy area: Health
Subjects: Cardiovascular and respiratory health

Drug safety, medical device, and laboratory regulation

Drug therapy

Emergency medical services and trauma care

Infectious and parasitic diseases
Latest action: action_date: 2022-03-09
text: Motion to Discharge Committee filed by Mr. Schweikert. Petition No: 117-11. (<a href="https://clerk.house.gov/DischargePetition/2022030911?Page=2&CongressNum=117">Discharge petition</a> text with signatures.)

Summaries:
action_date: 2021-11-17
action_desc: Introduced in House
text: <p><strong>Pandemic Cessation Act</strong></p> <p>This bill automatically terminates the COVID-19 public health emergency declared on January 31, 2020, when the Food and Drug Administration approves a new drug (or authorizes the emergency use of a drug) to treat COVID-19.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 6009 IN THE HOUSE OF REPRESENTATIVES November 17, 2021 Mr. Schweikert (for himself, Mr. Fallon , and Mr. Gohmert ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To provide that the public health emergency declared with respect to COVID–19 shall terminate on the date on which the Secretary of Health and Human Services approves, or authorizes emergency use of, a drug intended to treat COVID–19.

1. Short title This Act may be cited as the Pandemic Cessation Act . 2. Termination of COVID–19 public health emergency (a) In general The public health emergency declared pursuant to section 319 of the Public Health Service Act ( 42 U.S.C. 247d ) on January 31, 2020, with respect to COVID–19, and any renewal thereof, shall terminate on the first date after the date of enactment of this Act on which the Secretary of Health and Human Services— (1) grants approval under section 505 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 ) to an application with respect to a new drug intended to treat COVID–19; or (2) authorizes emergency use under section 564 of such Act ( 21 U.S.C. 360bbb–3 ) with respect to a drug intended to treat COVID–19. (b) Definition In this section, the terms drug and new drug have the meanings given such terms in section 201 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 321 ).